Bladder Cancer

A miRNA Signature Predicts Benefit from Addition of Hypoxia-Modifying Therapy to Radiation Treatment in Invasive Bladder Cancer - Beyond the Abstract July 29, 2021

Oncological Outcomes of High-Grade T1 Non-Muscle-Invasive Bladder Cancer Treatment in Octogenarians - Beyond the Abstract July 26, 2021

WANTED: The T-cells Responsible for Cancer Immunotherapy - Beyond the Abstract July 26, 2021

Active Surveillance for Non-Muscle Invasive Bladder Cancer: A Systematic Review and Pooled-Analysis - Beyond the Abstract July 22, 2021

Macro and Microeconomics of Blue Light Cystoscopy with CYSVIEW® in Non-Muscle Invasive Bladder Cancer - Beyond the Abstract July 19, 2021

Rapamycin Enhances BCG-Specific γδ T Cells During Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer: A Randomized, Double-Blind Study - Beyond the Abstract July 13, 2021

Pulsed Lasers and Endocorporeal Laser Lithotripsy – Beyond the Abstract July 13, 2021

First Time Intravesically Administered Trifunctional Antibody Catumaxomab in Patients with Recurrent Non-Muscle Invasive Bladder Cancer – Beyond the Abstract July 1, 2021

Intermediate- and High-Risk Nonmuscle Invasive Bladder Cancer: Where Do We Stand? - Beyond the Abstract June 30, 2021

Novel Roles of the Androgen Receptor in Bladder Cancer - Beyond the Abstract June 29, 2021

SAUL, a Single-Arm Study of Atezolizumab for Chemotherapy-Pretreated Locally Advanced or Metastatic Carcinoma of the Urinary Tract: Outcomes by Key Baseline Factors, PD-L1 Expression and Prior Platinum Therapy - Beyond the Abstract June 21, 2021

Comparison of Patient-reported Health-related Quality of Life Between Open Radical Cystectomy and Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Interim Analysis of a Randomised Controlled Trial - Beyond the Abstract June 18, 2021

Efficacy of Three BCG Strains (Connaught, TICE and RIVM) with or Without Secondary Resection (Re-TUR) for Intermediate/high-Risk Non-Muscle-Invasive Bladder Cancers: Results from a Retrospective Single-Institution Cohort Analysis - Beyond the Abstract June 18, 2021

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial – Beyond the Abstract June 14, 2021

Clinical Outcomes of Platinum-Ineligible Patients with Advanced Urothelial Carcinoma Treated with First-Line PD1/L1 Inhibitors - Beyond the Abstract June 2, 2021

Implications of Guideline-Based, Risk-Stratified Restaging Transurethral Resection of High-Grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes - Beyond the Abstract May 18, 2021

Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab - Beyond the Abstract May 14, 2021

Heated Intravesical Chemotherapy: Biology and Clinical Utility - Beyond the Abstract April 29, 2021

Defining Cisplatin Eligibility in Patients with Muscle-Invasive Bladder Cancer - Beyond the Abstract April 14, 2021

Clinical Trial of High Dose Hyperthermic Intravesical Mitomycin C for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer During BCG Shortage - Beyond the Abstract April 1, 2021

Page 1 of 17